Before revision: Data Exclusivity Period for human use drugs United States: 5 Years for new pharmaceutical chemical entities, 3 years for new indications for pharmaceutical drugs, and 12 years for biologic products.
After revision: Data exclusivity period for human-use drugs United States: 5 years for new pharmaceutical chemical entities, 3 years for new indications for pharmaceutical drugs, and 12 years for biologic products.